Posted by AGORACOM
at 8:05 AM on Thursday, March 4th, 2021
Rebranding Reflects XPhyto’s Commitment To Operational Achievement
Product Development Advance From The Lab To The Clinic
Cusp Of Two Major Commercial Milestones Related To Our Rapid Point-Of-Care COVID-19 PCR Test System
A Bioscience Accelerator At The Leading-Edge Of The Life Science Industry
XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) (“XPhyto” or the “Company”), is pleased to announce that the Company has completed a corporate rebranding and launched a new website which can be viewed at www.xphyto.com.
The rebranding decision reflects the Company’s commitment to operational achievement in 2021 as a number of product development programs advance from the laboratory to the clinic. As a bioscience accelerator at the leading-edge of the life science industry, XPhyto is targeting value creation through commercialization of its development pipeline and focused investment in impact driven innovation.
“The Company is excited to introduce a fresh look at such a pivotal point in our business growth,” said Hugh Rogers, CEO & Director of XPhyto. “With all technical requirements fulfilled, we are on the cusp of two major commercial milestones related to our rapid point-of-care COVID-19 PCR test system. With expected ISO certification and CE-IVD approval pending, we are excited to enter the next phase of our business with a positive, crisp and energetic new image.”
The Company will provide further information and updates in due course. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic. Further, its COVID-19 related test products are not yet approved and are still subject to risks associated with the regulatory approval process.
Posted by AGORACOM-JC
at 5:30 PM on Wednesday, March 3rd, 2021
Mountain Valley MD takes existing Vaccines & Drugs and delivers them better. Into the body better and by transportation. MVMD’s solubility technology applied to the Ivermectin drug is the only form in the world that are currently approved by the US Food and Drug Administration (FDA), making it a leading candidate for human injection and sublingual applications.
To this end they have created Ivectosol™ and it could be a massive disruption in the Vaccine Industry.
If you are looking to learn more about vaccine technologies. This video is a must watch with Dennis Hancock & Mike Farber of MVMD.
See how Mountain Valley MD is doing more with less.
Posted by AGORACOM
at 10:03 AM on Wednesday, March 3rd, 2021
Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) (“Red Light Holland” or the “Company”) is pleased to announce the launch of its Virtual Telecounseling membership program on the Company’s iMicrodose Digital Care App in the Netherlands. The app currently in use by consumers, is accessible from phones, tablets or computers. The telecounseling membership program will be seamlessly integrated into the privacy first iMicro Digital Care web app creating a new frontier for virtual psychedelic platforms. Online support will be offered to adults exploring microdosing with iMicrodose packs powered by Red Light Holland in the Netherlands. Members will be able to approve and share their iMicro Digital Care app data and connect with Red Light Holland’s certified therapist and microdosing expert, Jeff Hamburg, who will provide live virtual telecounseling. Adults can now register to the membership program by going to www.iMicrodose.nl.
“Red Light Holland is extremely proud to introduce virtual telecounseling, the use of digital information and communication technologies to help support the microdosing community. This is just another example of how we are promoting responsible use of our iMicrodose packs. This membership program will bring expert knowledge to the people in the Netherlands,” said Red Light Holland CEO and Director, Todd Shapiro. “I’m excited to have an experienced counselor like Jeff Hamburg connect with Red Light Holland consumers via telecounseling facilitating growth and wellbeing.”
“It’s thrilling to work with Red Light Holland, a company that is immediately building support structures for their customers. I’m excited to be able to offer my experience and knowledge on their consumer’s microdosing journey virtually through telecounseling on the iMicro Digital Care app,” said therapist and microdosing expert Jeff Hamburg.
The company will be offering two tiers of 3 month memberships:
(i) Growth Membership, priced at 75 euro: Includes bi-monthly online support group sessions led by Jeff Hamburg, textual consultation through the iMicro app, a monthly microdosing and creativity event as well as discounts and unique benefits for purchasing Red Light Holland merchandise.
(ii) Transform Membership, currently priced at a rate of 225 euro: For those who are interested in more personal one on one counseling with Jeff Hamburg. The transform membership will include 5 hour private sessions along with all benefits of the Growth membership.
Jeff Hamburg will also be offering short consultations for adults in the Netherlands curious to learn more about microdosing. Adults can register to the membership program or book a free consultation by going to www.iMicrodose.nl.
Posted by AGORACOM
at 9:58 AM on Wednesday, March 3rd, 2021
Royal Helium Ltd. (“Royal” or the “Company”) (TSXV: RHC) announces that it has engaged two service rigs and that the completions and testing program has been initiated at Climax-1 and Climax-2. The finalized testing program, which was developed in concert with Sproul Associates Ltd., involves the sequential perforation and gas flow testing of several separate intervals identified during drilling. Finalized results from the testing program will be reported as the information becomes available.
Royal further announces that the Climax-3 helium well has been drilled to its target depth of 2,600 metres. Royal’s completion team is reviewing the log data at Climax-3 to determine the intervals to be production tested. The completion and testing program at Climax-3 will commence once testing is complete on Climax-2.
Andrew Davidson, President and CEO of Royal comments, “We are pleased to have our initial 3 wells at Climax drilled to target depth and we are excited to be production testing these high value targets. We want to thank the team from Savanna 419 for their diligent work in completing this drilling program safely and effectively”.
Mr. Davidson continues “With 2 service rigs operating we anticipate the testing to be completed on all 3 wells over the next few weeks. While any significant developments will be announced as they are received, all results will be evaluated by Sproule for a potential helium resource and production over multiple separate zones within this large structural closure”.
The three Climax wells were drilled into the Precambrian basement, directly below the Deadwood Formation. The Deadwood is a sand and shale sequence that is a known helium production zone in Saskatchewan. These first three wells are targeting different parts of the same large structural trap identified on the central portion of the Climax land block.
Posted by AGORACOM
at 9:54 AM on Wednesday, March 3rd, 2021
Mountain Valley MD Holdings Inc.(the “Company” or “MVMD“) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce it has contracted Camargo Pharmaceutical Services, LLC (“Camargo”) to provide regulatory consulting services to support MVMD’s pursuit of U.S. Food and Drug Administration (FDA) approval of its novel Ivectosol™ rapid dissolve oral format.
Camargo is recognized as one of the most experienced global organizations who specialize in drug and combination device product development and approval utilizing the regulatory pathway provided for in Section 505(b)(2) of the US Federal Food, Drug, and Cosmetic Act. Over the last decade, Camargo has established a leading track record with 505(b)(2) investigational new drug (“IND”) and new drug applications (“NDA” preparations and submissions, including participation in more than 1100 Agency meetings and more than 200 FDA NDA and ANDA (Abbreviated New Drug Applications) approvals.
“After successful pre-clinical studies of our novel solubilized Ivectosol™ sublingual in our pre-clinical trials, this is a critical next step in the approval process to support our human application objectives,” stated Mike Farber, Director of Life Sciences at Mountain Valley MD. “Camargo will be a great partner to accelerate our efforts for the initial pre-IND presentation to the FDA outlining Ivermectin’s prior usage history and extensive safety record for the FDA’s assessment and approval pathway.”
The 505(b)(2) new drug application is one of three U.S. Food and Drug Administration drug approval pathways and represents an appealing regulatory strategy by way of helping to avoid unnecessary duplication of studies already performed on a previously approved drug. The Company believes the 505(b)(2) pathway will result in a much less expensive and much faster route to approval, compared with a traditional development pathway, while creating a new, differentiated Ivermectin product with tremendous commercial value.
“Camargo is proud to partner with Mountain Valley MD to advance their novel solubilized Ivermectin sublingual wafer,” said Catherine Gatza, PhD, Vice President, Regulatory and Strategy at Camargo. “This program delivers important advantages to the parasitic infection treatment landscape by providing an alternative dosage form.”
As previously communicated, MVMD’s solubility technology applied to the Ivermectin drug is the only form in the world that uses strictly excipients that are currently approved by the US Food and Drug Administration (FDA), making it a leading candidate for human injection and sublingual applications as well as significantly broader husbandry and companion animal treatments based on its low viscosity.
“The U.S. FDA approval would prove the efficacy and safety of MVMD’s Ivectosol™ wafer at one of the highest standards in the world and would assist in facilitating greater access to key global markets in an accelerated capacity,” stated Dennis Hancock, President & CEO of Mountain Valley MD. “The human approval pathway timed with our aggressive pursuit of husbandry applications, is core to making our Ivectosol™ products the number one commercial form of Ivermectin in the world.”
Posted by AGORACOM
at 1:46 PM on Tuesday, March 2nd, 2021
RED LIGHT HOLLAND LAUNCHES NEW LOGO AND INTERACTIVE WISDOM TRUFFLE COMPANION CREATED BY INTERNATIONALLY RENOWNED & AWARD-WINNING DESIGNER KARIM RASHID
Red Light Holland Corp. has revealed the company’s interactive Wisdom Truffle and new logo carefully and creatively designed by renowned designer and head of design for Red Light Holland, Karim Rashid.
The Wisdom Truffle will be produced in three different models which is expected to be sold across the world in Q4 2021, and it will be able to be pre-ordered on the Company’s website by the end of March 2021. Each model will support a different aspect of Red Light Holland’s iMicro healthy lifestyle and work in conjunction with Red Light Holland’s iMicro Journal WebApp (currently in use) and the Company’s completed immersive AR/VR apps.
“While focusing on our core business, our goal is also to create alternative revenue streams while building a global brand that is electric, alive and genuinely connects – which then encourages a lifestyle of healthy daily habits, including disconnecting from technology and reconnecting with nature and ourselves for mental clarity,” said Red Light Holland CEO and Director Todd Shapiro. “I’m amazed to be part of such a creative team that is combining Karim Rashid’s designs and Radix Motion’s technology. Together we are kicking ass with this unique combination of tech meeting real life through creative minds from all sides.
The Red Light Holland team is proud to help you see things differently.”Wisdom Truffle Companion Image 3
“The design of the Wisdom Truffle companion promotes positivity and provides comfort. The Wisdom Truffle is also an incredible art piece that’s a great conversation starter around finding a healthier balance with our use of technology. Something we need now more than ever,” said Karim Rashid. “The three model sizes will fit different, use cases and together can transform any environment, bringing light, music and interactivity. The new logo reflects the Wisdom Truffle becoming Red Light Holland’s brand ambassador and it truly represents all of us proudly.”
Posted by AGORACOM-JC
at 10:20 AM on Tuesday, March 2nd, 2021
Experienced a significant surge in online demand for its products and has launched its own Amazon Brand Store on Amazon.com.
The new Else Nutrition online store front provides an improved user experience enabling seamless customer journeys in product purchase, alongside a growing product assortment while better communicating the Else brand story.
VANCOUVER, BC , March 2, 2021 –ELSE NUTRITION HOLDINGS INC.(TSXV: BABY ) (OTCQX: BABYF ) (FSE: 0YL ) (“Else” or the “Company”) the Plant-Based baby, toddler and children nutrition company announces today that it has experienced a significant surge in online demand for its products and has launched its own Amazon Brand Store on Amazon.com. The new Else Nutrition online store front provides an improved user experience enabling seamless customer journeys in product purchase, alongside a growing product assortment while better communicating the Else brand story.
“This takes us to the next level on Amazon,” said Hamutal Yitzhak , CEO and Co-Founder of Else Nutrition. “We’ve already been seeing great response on the platform, and this combination of enhanced customer experience and access to greater ad tools, enable us to scale much faster. We will continue to build our brand and boost visibility on Amazon,” she added.
Else Plant-Based Complete Toddler Nutrition was a #1 Best Seller on Amazon in the New Releases for the Baby/Toddler Formula category in Fall 2020. The 2-pack format, which was recently released, has already become the top seller in Amazon’s New Releases in the Baby Powder formula category.
Posted by AGORACOM
at 9:20 AM on Tuesday, March 2nd, 2021
Highlights:
Rhodium (Rh) is the most valuable platinum group metal (PGM), with recent spot price highs of over $US24,000/oz Rh, nearly 18 times higher than Pt
303 Rh assay results reported for the Pine Zone of the River Valley Deposit
Highest assay result is 0.177 g/t Rh, with 9 other samples returned assays at or greater than 0.100 g/t Rh and a total of 50 samples returned assays higher than 0.050 g/t Rh
The highest Rh concentrations coincide with the highest palladium (Pd) and platinum (Pt) grades – Rh concentrations in the River Valley Deposit are equivalent to 12% of the Pt grades
Based on encouraging results from phase 1, subsequent phases of the multi-phase Rh evaluation program will take samples of PGM mineralized intervals from the Dana South and Lismer zones
The River Valley Deposit is one of North Americas largest undeveloped primary platinum-group metal projects with 2.867 Moz Palladium Equivalent (PdEq) in the Measured + Indicated classifications and 1.059 Moz Pd Eq in the Inferred classification
New Age Metals Inc. (NAM) (TSXV:NAM); (OTC:NMTLF); (FSE:P7J) (“NAM” or the “Company”) announces completion of Phase 1 of an ongoing Rh assay program on the River Valley Palladium Deposit near Sudbury, Ontario (Figure 1). Phase 1 of the Rh assay program collected 303 pulp samples from 17 mineralized intervals in 14 drill holes through the Pine Zone. The samples were selected to provide Rh data for mineralization in two cross-sections spaced 50 metres apart through the Pine Zone, located near the north end of the 16 km long River Valley Deposit (Figure 1). In addition to Rh, the samples were also assayed for gold (Au), iridium (Ir), palladium (Pd), platinum (Pt), and ruthenium (Ru). The assays were completed on 2015-2020 drill core sample pulps at the Geoscience Laboratories in Sudbury.
Posted by AGORACOM
at 8:31 AM on Tuesday, March 2nd, 2021
Conducting survey to delineate Nickel targets north of Kenbridge deposit
TDEM surveys have been used extensively and successfully to aid in identifying nickel sulphide targets
Next step is to move the Kenbridge Deposit towards a Bankable Feasibility Study
Tartisan is planning a late spring early summer drill program
Tartisan Nickel Corp. (CSE:TN)(OTC Pink:TTSRF)(FSE:A2D) (“Tartisan”, or the “Company”) is pleased to provide an update on the 100% owned Kenbridge Nickel Project in Northwestern Ontario. The Company has contracted Crone Geophysics & Exploration Ltd to complete a surface Time Domain Electromagnetic (TDEM) survey over targets identified to the north of the known Kenbridge Ni-Cu-Co Deposit. The target areas are interpreted to represent similar rock types which host the Kenbridge Deposit. TDEM surveys have been used extensively and successfully to aid in identifying nickel sulphide targets like the Kenbridge Ni-Cu-Co Deposit.
The Company recently released an Updated Mineral Resource Estimate (MRE) for the Kenbridge Nickel-Copper-Cobalt Project, Atikwa Lake Area, Northwestern Ontario (press released September 17, 2020). Tartisan Nickel Corp. subsequently announced that P&E Mining Consultants Inc. have been contracted to oversee the updating of the Preliminary Economic Assessment Technical Report (“PEA”) on the Kenbridge Project (press released February 2, 2021). The “PEA” will identify the critical next steps that Tartisan needs to take to move the Kenbridge Deposit towards a Bankable Feasibility Study including permitting, geotechnical, environmental, and geological considerations.
Mark Appleby, CEO of Tartian Nickel Corp. states; “the geophysical field crew is expected to mobilize to site in the next 2 weeks. Tartisan is planning a late spring early summer drill program on the down plunge and down dip extensions to the known deposit and will look to drill targets generated from the TDEM program”. Appleby goes on to state “Tartisan will aggressively move the Kenbridge Nickel Project forward in 2021”.
Posted by AGORACOM-JC
at 4:17 PM on Monday, March 1st, 2021
Last week we introduced you to ORTHO Regenerative Technologies, a cutting-edge med tech firm that uses its proprietary RESTORE technology platform to dramatically improve the success rate of orthopedic and sports medicine surgeries.
In layman’s terms, that means company has a wonder delivery platform that delivers biologics – drugs made from biological processes – to repair soft tissues in the human body.
Now the firm has appointed Patrick O’Donnell to its board of directors.
O’Donnell comes with significant company-building experience
He will prove crucial in putting this healthcare pioneer on-track for a NASDAQ listing
Claude LeDuc, Ortho’s CEO, breaks down the appointment:
